Karen MacDonald
About
Karen MacDonald is a scholar working on Oncology, Immunology and Hematology.
According to data from OpenAlex, Karen MacDonald has authored 127 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 26 papers in Immunology and 25 papers in Hematology. Recurrent topics in Karen MacDonald's work include Neutropenia and Cancer Infections (32 papers), Biosimilars and Bioanalytical Methods (25 papers) and Health Systems, Economic Evaluations, Quality of Life (15 papers). Karen MacDonald is often cited by papers focused on Neutropenia and Cancer Infections (32 papers), Biosimilars and Bioanalytical Methods (25 papers) and Health Systems, Economic Evaluations, Quality of Life (15 papers). Karen MacDonald collaborates with scholars based in United States, Switzerland and Belgium. Karen MacDonald's co-authors include Ivo Abraham, Christopher S. Lee, Ivo Abraham, David Feifel, W. Monaghan, C.D.W. Wilkinson, Adam Curtis, Beata Wójciak‐Stothard, Abdulaziz Alhossan and Kris Denhaerynck and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
In The Last Decade
Karen MacDonald
121 papers receiving 2.7k citations
Hit Papers
Peers
Karen MacDonald
Kim Hørslev‐Petersen Denmark
Torkell Ellingsen Denmark
Robert W. Simms United States
Peter Chang United States
Björn Svensson Sweden
Henry E. Rice United States
Sedat Kiraz Türkiye
Simon Carette Canada
Steven R. Ytterberg United States
Andrea Wang United States
Citations per year, relative to Karen MacDonald Karen MacDonald (= 1×)
peers
Kim Hørslev‐Petersen
Countries citing papers authored by Karen MacDonald
Since
Specialization
Citations
This map shows the geographic impact of Karen MacDonald's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen MacDonald with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen MacDonald more than expected).
Fields of papers citing papers by Karen MacDonald
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Karen MacDonald. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen MacDonald. The network helps show where Karen MacDonald may publish in the future.
Co-authorship network of co-authors of Karen MacDonald
This figure shows the co-authorship network connecting the top 25 collaborators of Karen MacDonald. A scholar is included among the top collaborators of Karen MacDonald based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen MacDonald. Karen MacDonald is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
MacDonald, Karen, et al.. (2024). Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma. Journal of Medical Economics. 27(sup3). 1–8.
2.
Combe, Christian, Johannes F.E. Mann, David Goldsmith, et al.. (2019). Potential life-years gained over a 5-year period by correcting DOPPS-identified modifiable practices in haemodialysis: results from the European MONITOR-CKD5 study. BMC Nephrology. 20(1). 81–81.
3.
McBride, Ali, et al.. (2017). Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. Journal of Medical Economics. 20(10). 1083–1093.
4.
Jacob, Julie A., et al.. (2017). Six-year outcomes in neovascular age-related macular degeneration with ranibizumab. International Journal of Ophthalmology. 10(1). 81–90.
5.
Denhaerynck, Kris, Abdulaziz Alhossan, Stefaan Vancayzeele, et al.. (2017). Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Hypertensive Patients with and without Diabetes: Pooled Analysis of Six Observational Valsartan Studies with 15,282 Evaluable Patients. SHILAP Revista de lepidopterología. 2017. 1–11.
6.
Aapro, Matti, Carsten Bokemeyer, Mario Boccadoro, et al.. (2017). Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in solid tumours versus haematological malignancies: Patterns, outcomes and determinants (MONITOR-GCSF study). Annals of Oncology. 28. x158–x158.
7.
Bokemeyer, Carsten, Pere Gascón, Matti Aapro, et al.. (2017). Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study. Supportive Care in Cancer. 25(6). 1819–1828.
8.
Westblade, Lars F., Omai B. Garner, Karen MacDonald, et al.. (2015). Assessment of Reproducibility of Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry for Bacterial and Yeast Identification. Journal of Clinical Microbiology. 53(7). 2349–2352.
9.
Sun, Diana, Tri Murti Andayani, Ahmed E. Altyar, Karen MacDonald, & Ivo Abraham. (2015). Potential Cost Savings From Chemotherapy-Induced Febrile Neutropenia With Biosimilar Filgrastim and Expanded Access to Targeted Antineoplastic Treatment Across the European Union G5 Countries: A Simulation Study. Clinical Therapeutics. 37(4). 842–857.
10.
Gesualdo, Loreto, Christian Combe, Adrian Covic, et al.. (2015). Risk-based individualisation of target haemoglobin in haemodialysis patients with renal anaemia in the post-TREAT era: theoretical attitudes versus actual practice patterns (MONITOR-CKD5 study). International Urology and Nephrology. 47(5). 837–845.
11.
Abraham, Ivo, et al.. (2015). Detectability and acceptability of continuous pulse signals for the MemoPatch® device, an electronic skin patch intended to deliver tactile medication reminder signals. Medical Devices Evidence and Research. 8. 119–119.
12.
Zapata, Lorenzo Villa, Ivo Abraham, Karen MacDonald, & Kris Denhaerynck. (2011). PCV107 Correlation of Physician-Rated Adherence with Therapeutical Outcomes in Antihypertensive Treatment: Pooled Analysis Findings from Six Valsartan Studies Including 15,583 Available Patients. Value in Health. 14(7). A383–A384.
13.
Abraham, Ivo, Karen MacDonald, MinKyoung Song, et al.. (2011). Patient- and physician-level determinants of blood pressure response to treatment in normal weight and overweight patients (the PREVIEW study). Nutrition Metabolism and Cardiovascular Diseases. 23(4). 314–322.
14.
Abraham, Ivo, Christopher S. Lee, MinKyoung Song, et al.. (2010). “Later, lazier, and unluckier”: a heuristic profile of high vulnerability is an independent predictor of uncontrolled blood pressure (the PREVIEW study). PubMed Central.
15.
Gascón, Pere, Matti Aapro, Heinz Ludwig, et al.. (2010). Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim. Critical Reviews in Oncology/Hematology. 77(3). 184–197.
16.
Abraham, Ivo, Karen MacDonald, Christopher S. Lee, et al.. (2009). Hierarchical linear and logistic modeling of outcomes of antihypertensive treatment in elderly patients: Findings from the PREVIEW study. Archives of Gerontology and Geriatrics. 51(1). 45–53.
17.
Aapro, Matti, Ivo Abraham, Carsten Bokemeyer, et al.. (2007). The background and methodology of the Anaemia Cancer Treatment (A.C.T.) study: a global retrospective study of practice patterns and outcomes in the management of anaemia in cancer patients and their congruence with evidence-based guidelines. Supportive Care in Cancer. 16(2). 193–200.
18.
Aapro, Matti, Karen MacDonald, Pierre Soubeyran, et al.. (2007). Promoting evidence-based management of anemia in cancer patients: Background, development, and scientific validation of RESPOND, a web-based clinical guidance system based on the EORTC guidelines. Critical Reviews in Oncology/Hematology. 65(1). 32–42.
19.
Richards, David, Kristi A. Boehm, David Waterhouse, et al.. (2006). Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study. Annals of Oncology. 17(7). 1096–1102.
20.
Kyle, Phillipa M., et al.. (1994). Life without amniocentesis: elevated maternal serum α‐fetoprotein in the Manitoba program 1986–91. Ultrasound in Obstetrics and Gynecology. 4(3). 199–204.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Kim Hørslev‐Petersen Breakdown of academic impact, for papers by Torkell Ellingsen Breakdown of academic impact, for papers by Robert W. Simms Breakdown of academic impact, for papers by Peter Chang Breakdown of academic impact, for papers by Björn Svensson Breakdown of academic impact, for papers by Henry E. Rice Breakdown of academic impact, for papers by Sedat Kiraz Breakdown of academic impact, for papers by Simon Carette Breakdown of academic impact, for papers by Steven R. Ytterberg Breakdown of academic impact, for papers by Andrea Wang